Intensity Therapeutics, Inc. Common stock (INTS)vsNovartis AG ADR (NVS)
INTS
Intensity Therapeutics, Inc. Common stock
$5.21
+0.06%
HEALTHCARE · Cap: $13.80M
NVS
Novartis AG ADR
$148.34
+1.95%
HEALTHCARE · Cap: $275.95B
Smart Verdict
WallStSmart Research — data-driven comparison
NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
INTS
Avoid23
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INTS.
Margin of Safety
-52.0%
Fair Value
$109.95
Current Price
$148.34
$38.39 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : INTS
The strongest argument for INTS centers on Price/Book.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : INTS
The primary concerns for INTS are Revenue Growth, EPS Growth, Market Cap.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
INTS profiles as a value stock while NVS is a declining play — different risk/reward profiles.
INTS carries more volatility with a beta of 3.26 — expect wider price swings.
INTS is growing revenue faster at 0.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 23/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Intensity Therapeutics, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
Intensity Therapeutics, Inc. is an innovative biotechnology firm dedicated to transforming cancer treatment through its advanced drug delivery systems. The company specializes in enhancing the effectiveness of immuno-oncology therapies while reducing systemic side effects, effectively addressing significant unmet needs in oncology. With a strong emphasis on cutting-edge research and development, Intensity Therapeutics is strategically positioned to spearhead advancements in targeted therapies, aiming to bolster the body's immune response against cancer and ultimately improve patient outcomes.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?